Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06397885
Other study ID # CP0004
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 30, 2024
Est. completion date April 30, 2025

Study information

Verified date April 2024
Source Materna Medical
Contact Sheryl Kingsberg, Ph.D
Phone 866-433-6933
Email POMPOM@hellomilli.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To assess the effectiveness of the Milli device in achieving vaginal intercourse


Description:

The Milli Vaginal Dilator is a patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion. This study is intended to provide data in support of the Milli Vaginal Dilator as a commercially available, over-the-counter medical device. The Milli has been granted marketing authorization by the FDA under premarket notification K220035 for the following Indications for Use statement: The Milli Vaginal Dilator is a tool indicated for controlled dilation of the vagina. It can be used for dilation for an examination (by your doctor), in preparation for a surgical procedure, or to help relieve the symptoms of vaginismus (condition that involves tightening of the vaginal muscles) and related painful sex. .


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 30, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is a female at birth aged =18 years of age - Subject is able to read and understand the approved, informed consent form (ICF) - Subject meets vaginismus and related painful sex/GPPPD criteria as defined in the DSM-5, as confirmed by having one or more of the following for greater than 6 months: - Pelvic pain - Vaginal pain - Pain with vaginal intercourse - Pain with vaginal penetration - Fear or anxiety about vaginal or pelvic pain with vaginal penetration - The inability to achieve vaginal penetration - Subject currently has a sexual partner with a functional penis - Subject is currently seeking vaginal penetration to achieve sexual intercourse - Subject is currently unable to tolerate vaginal penetration to achieve sexual intercourse (Score of =1 on PEQ Question #1) - Subject purchased Milli vaginal dilator - Subject is not contraindicated for Milli vaginal dilator use - Subject is able and willing to comply with study protocol Exclusion Criteria: - Subject has previously participated in any studies by the company in the past 12 months or has used Milli prior to enrollment - Subject is pregnant - Subject has an active pelvic infection (vagina or vulva) - Subject has open wounds in the tissue inside or surrounding the vagina - Subject has an untreated major mental health disorder (e.g., affective disorder, psychosis, PTSD) - Subject has prior history of gender-confirming surgery, vaginal reconstruction surgery, pelvic radiation, and/or vaginal procedures that result in extensive scarring (with the exception of hysterectomy procedures) - Subject or subject's partner experiences other conditions preventing intercourse (e.g., erectile dysfunction, lack of libido)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Milli Vaginal Dilator
Patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion

Locations

Country Name City State
United States Materna Clinic Mountain View California

Sponsors (1)

Lead Sponsor Collaborator
Materna Medical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Penetration Efficiency Questionnaire Ability to achieve full vaginal penetration with the penis of the partner (intercourse) as measured by the Penetration Efficiency Questionnaire (Score of =2 on PEQ Question #1) at six months 6 months
Secondary Penetration Efficiency Questionnaire Ability to achieve full vaginal penetration with the penis of the partner (intercourse) as 3 months
Secondary Penetration Efficiency Questionnaire Improvement in ability to achieve vaginal penetration (intercourse and non-intercourse) as measured by a change in baseline in the overall score on the Penetration Efficiency Questionnaire at 3 and 6 months. 3 months, 6 months
Secondary Female Sexual Function Index (FSFI) Improvement in self-reported sexual function as reported on a change in baseline in the Female Sexual Function Index (FSFI) total score at 3 and 6 months. 3 months, 6 months
Secondary Numerical Rating Scale Improvement in self-reported pain intensity with intercourse as reported as a change in baseline on a numeric rating scale (NRS) (0= no pain, 10 = worst pain imaginable) at 3 and 6 months 3 months, 6 months
See also
  Status Clinical Trial Phase
Completed NCT03935698 - Physiotherapy Treatment in Women With Dyspareunia Following Gynecological Cancer: a Pilot Study N/A
Recruiting NCT03427255 - CBT Group Treatment for Women With Dyspareunia N/A
Completed NCT02253173 - Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women Phase 3
Completed NCT03184077 - Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair N/A
Recruiting NCT05445115 - The Mollie Study, a Study to Evaluate the Safety and Efficacy of the Mollie Medical Device N/A
Withdrawn NCT03666819 - Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Phase 2
Active, not recruiting NCT03681678 - Laser Therapy for Treatment of Urogenital Symptoms in Women
Completed NCT04955418 - Effects of Epi-no Device on Pelvic Floor Dysfunctions N/A
Completed NCT05834088 - Effects of Myofascial Release With and Without Thiele Massage N/A
Terminated NCT03185169 - GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors Early Phase 1
Completed NCT03307044 - Fractional CO2 Laser Therapy for Survivors of Breast Malignancies N/A
Completed NCT05617820 - Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy Phase 3
Recruiting NCT03714581 - Laser Therapy Following Radiotherapy for Gynecological Cancer N/A
Completed NCT04659668 - Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina. N/A
Completed NCT03199534 - A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction Phase 4
Completed NCT00318500 - Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women Phase 2
Recruiting NCT05540353 - Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients With Endometriosis. N/A
Completed NCT03178825 - Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause N/A
Completed NCT04389489 - Postpartum Sexual Function in Pregnant Women With COVID-19
Completed NCT03372720 - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors N/A